The effects of the integration of an economic strengthening and HIV prevention education programme on the prevalence of sexually transmitted infections and savings behaviours among adolescents: a full-factorial randomised controlled trial in South Africa.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
2020
Historique:
received: 27 09 2019
revised: 15 02 2020
accepted: 28 02 2020
entrez: 2 5 2020
pubmed: 2 5 2020
medline: 25 6 2021
Statut: epublish

Résumé

Multisectoral approaches are thought necessary to prevent HIV among adolescents. We examined whether an economic strengthening (ES) and an HIV-prevention education intervention improved outcomes when combined versus separately. We conducted a full-factorial randomised controlled study to randomise participants into all possible intervention groups based on the two interventions: economic strengthening only (ES-only), HIV-prevention only (HIV-only), both interventions combined (ES+HIV) and no intervention (control). We measured sexually transmitted infections (STIs), self-reported economic and sexual behaviours/knowledge, and pregnancy at a pre-intervention and two post-intervention assessments. Eligible participants were adolescents 14 to 17 years old from a programme supporting vulnerable families in Gauteng Province, South Africa. We estimated intervention effects using repeated measures, generalised linear mixed models. A total of 1773 adolescents participated (57% female). ES+HIV adolescents had the lowest STI prevalence at first endline; however, the comparison with the control was not significant (OR 0.62, 95% CI 0.27 to 1.41). ES-only or HIV-only groups were not significantly better than the control on STI prevalence (OR 1.53, 95% CI 0.73 to 3.20 and OR 1.47, 95% CI 0.69 to 3.12, respectively). STI prevalence became more similar among the groups at second endline.ES-only adolescents were more likely to participate in savings groups (p=0.004) and plan to save for education (p=0.001) versus the control. ES+HIV adolescents were more likely to plan to save for education versus the control (p=0.001) and HIV-only groups (p=0.002) but did not differ significantly from the ES-only group (p=0.803). The ES+HIV intervention's effect on HIV knowledge was significant compared with the control (p=0.03) and ES-only groups (p<0.001), but not when compared with the HIV-only group (p=0.091). Effects on pregnancy, sexual behaviours or other economic behaviours were not significant. We could not confirm the ES and HIV interventions, separately or combined, were effective to reduce STI prevalence. Evaluations of multicomponent interventions should use full-factorial designs to fully assess effects. NCT02888678.

Sections du résumé

Background
Multisectoral approaches are thought necessary to prevent HIV among adolescents. We examined whether an economic strengthening (ES) and an HIV-prevention education intervention improved outcomes when combined versus separately.
Methods
We conducted a full-factorial randomised controlled study to randomise participants into all possible intervention groups based on the two interventions: economic strengthening only (ES-only), HIV-prevention only (HIV-only), both interventions combined (ES+HIV) and no intervention (control). We measured sexually transmitted infections (STIs), self-reported economic and sexual behaviours/knowledge, and pregnancy at a pre-intervention and two post-intervention assessments. Eligible participants were adolescents 14 to 17 years old from a programme supporting vulnerable families in Gauteng Province, South Africa. We estimated intervention effects using repeated measures, generalised linear mixed models.
Results
A total of 1773 adolescents participated (57% female). ES+HIV adolescents had the lowest STI prevalence at first endline; however, the comparison with the control was not significant (OR 0.62, 95% CI 0.27 to 1.41). ES-only or HIV-only groups were not significantly better than the control on STI prevalence (OR 1.53, 95% CI 0.73 to 3.20 and OR 1.47, 95% CI 0.69 to 3.12, respectively). STI prevalence became more similar among the groups at second endline.ES-only adolescents were more likely to participate in savings groups (p=0.004) and plan to save for education (p=0.001) versus the control. ES+HIV adolescents were more likely to plan to save for education versus the control (p=0.001) and HIV-only groups (p=0.002) but did not differ significantly from the ES-only group (p=0.803). The ES+HIV intervention's effect on HIV knowledge was significant compared with the control (p=0.03) and ES-only groups (p<0.001), but not when compared with the HIV-only group (p=0.091). Effects on pregnancy, sexual behaviours or other economic behaviours were not significant.
Conclusions
We could not confirm the ES and HIV interventions, separately or combined, were effective to reduce STI prevalence. Evaluations of multicomponent interventions should use full-factorial designs to fully assess effects.
Trial registration number
NCT02888678.

Identifiants

pubmed: 32355569
doi: 10.1136/bmjgh-2019-002029
pii: bmjgh-2019-002029
pmc: PMC7179044
doi:

Banques de données

ClinicalTrials.gov
['NCT02888678']

Types de publication

Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e002029

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Authors do not have any potential, perceived or real conflict of interest to declare. The study sponsor (USAID) was involved in the study design by requesting the authors to evaluate the intervention in South Africa and they also reviewed the protocol.

Références

AIDS. 2010 Oct;24 Suppl 4:S70-80
pubmed: 21042055
Afr J AIDS Res. 2016;15(1):67-75
pubmed: 27002359
AIDS Behav. 2016 Jan;20 Suppl 1:S215-7
pubmed: 26459333
Sex Transm Infect. 2015 Nov;91(7):528-33
pubmed: 25587182
AIDS. 2008 Aug 20;22(13):1659-65
pubmed: 18670227
Afr J AIDS Res. 2005 May;4(1):37-50
pubmed: 25865640
Curr HIV/AIDS Rep. 2015 Jun;12(2):207-15
pubmed: 25855338
AIDS Res Ther. 2014 Sep 15;11:31
pubmed: 25243015
Trop Med Int Health. 2012 Jul;17(7):796-807
pubmed: 22594660
Am J Public Health. 2006 Jun;96(6):1085-90
pubmed: 16670238
Bull World Health Organ. 2009 Nov;87(11):824-32
pubmed: 20072767
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Glob Health. 2013 Dec;1(6):e362-70
pubmed: 25104601
Lancet Glob Health. 2016 Dec;4(12):e978-e988
pubmed: 27815148
AIDS Behav. 2016 Sep;20(9):1863-82
pubmed: 26891839
Lancet. 2008 Aug 30;372(9640):764-75
pubmed: 18687460
BMJ. 2008 Aug 07;337:a506
pubmed: 18687720
Glob Health Action. 2017 Jan - Dec;10(sup2):1290427
pubmed: 28467193
J Int AIDS Soc. 2011 May 18;14:25
pubmed: 21592368
Pediatrics. 2011 Feb;127(2):208-13
pubmed: 21199852
AIDS Care. 2018;30(sup3):85-98
pubmed: 29985055
AIDS Behav. 2010 Dec;14(Suppl 2):204-21
pubmed: 20862606
BMC Public Health. 2010 Feb 26;10:102
pubmed: 20187957
J Int AIDS Soc. 2016 Dec 26;19(1):21310
pubmed: 28364564
Reprod Health Matters. 2001 May;9(17):82-90
pubmed: 11468850
J Adolesc Health. 2009 Dec;45(6):595-601
pubmed: 19931832
Gates Open Res. 2018 May 29;1:6
pubmed: 29984355
J Adolesc. 2013 Dec;36(6):1177-86
pubmed: 24215964
Stud Fam Plann. 2014 Mar;45(1):43-58
pubmed: 24615574
Soc Sci Med. 2003 Jan;56(1):149-65
pubmed: 12435558
BMC Public Health. 2014 Dec 29;14:1325
pubmed: 25544716
Behav Res Methods. 2015 Dec;47(4):1237-1259
pubmed: 25410404
AIDS Care. 2016;28 Suppl 1:8-15
pubmed: 26886261
PLoS One. 2014 Nov 21;9(11):e113621
pubmed: 25415455
Lancet. 2010 Jul 3;376(9734):41-8
pubmed: 20557928
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
BMC Med Res Methodol. 2013 Jan 31;13:11
pubmed: 23368888
AIDS. 2008 Jan 30;22(3):403-14
pubmed: 18195567
J Adolesc Health. 2007 Mar;40(3):206-17
pubmed: 17321420
Am J Reprod Immunol. 2013 Feb;69 Suppl 1:27-40
pubmed: 23176109
J Int AIDS Soc. 2012;15 Suppl 1:1-4
pubmed: 22905346
Arch Sex Behav. 1998 Apr;27(2):155-80
pubmed: 9562899
Stud Fam Plann. 2008 Dec;39(4):321-34
pubmed: 19248718

Auteurs

Holly M Burke (HM)

Reproductive, Maternal, Newborn, and Child Health, FHI 360, Durham, North Carolina, USA.

Mario Chen (M)

Biostatistics, FHI 360, Durham, North Carolina, USA.

Kate Murray (K)

Reproductive, Maternal, Newborn, and Child Health, FHI 360, Durham, North Carolina, USA.

Charl Bezuidenhout (C)

Research Unit, Foundation for Professional Development, Pretoria, South Africa.

Phuti Ngwepe (P)

Research Unit, Foundation for Professional Development, Pretoria, South Africa.

Alissa Bernholc (A)

Biostatistics, FHI 360, Durham, North Carolina, USA.

Andrew Medina-Marino (A)

Research Unit, Foundation for Professional Development, Pretoria, South Africa.
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH